- Home
- HLF vs KROS Comparison
HLF vs KROS Comparison
Compare HLF & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLF
- KROS
- Stock Information
- Founded
- HLF 1980
- KROS 2015
- Country
- HLF United States
- KROS United States
- Employees
- HLF N/A
- KROS N/A
- Industry
- HLF Other Pharmaceuticals
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- HLF Health Care
- KROS Health Care
- Exchange
- HLF Nasdaq
- KROS Nasdaq
- Market Cap
- HLF 663.7M
- KROS 589.8M
- IPO Year
- HLF N/A
- KROS 2020
- Fundamental
- Price
- HLF $6.59
- KROS $11.41
- Analyst Decision
- HLF Buy
- KROS Buy
- Analyst Count
- HLF 5
- KROS 11
- Target Price
- HLF $9.90
- KROS $45.33
- AVG Volume (30 Days)
- HLF 2.1M
- KROS 2.0M
- Earning Date
- HLF 02-19-2025
- KROS 02-26-2025
- Dividend Yield
- HLF N/A
- KROS N/A
- EPS Growth
- HLF N/A
- KROS N/A
- EPS
- HLF 0.85
- KROS N/A
- Revenue
- HLF $5,000,700,000.00
- KROS $651,000.00
- Revenue This Year
- HLF N/A
- KROS $303.27
- Revenue Next Year
- HLF $1.57
- KROS N/A
- P/E Ratio
- HLF $7.80
- KROS N/A
- Revenue Growth
- HLF N/A
- KROS 8037.50
- 52 Week Low
- HLF $6.05
- KROS $9.78
- 52 Week High
- HLF $12.90
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- HLF 42.84
- KROS 22.44
- Support Level
- HLF $6.05
- KROS $9.78
- Resistance Level
- HLF $7.01
- KROS $11.63
- Average True Range (ATR)
- HLF 0.26
- KROS 0.89
- MACD
- HLF 0.04
- KROS 1.07
- Stochastic Oscillator
- HLF 56.25
- KROS 23.61
About HLF Herbalife Ltd.
Herbalife Ltd is an international nutrition company that provides health and wellness products to consumers in 95 markets, which consist of countries and territories, through their direct-selling business model. Companies' products are weight management; targeted nutrition; Energy, Sports, and Fitness; Outer Nutrition and Literature, Promotional, and Other. Weight management generates the majority of revenue from products like Meal replacements, protein shakes, drink mixes, weight loss enhancers, and healthy snacks. Geographically, the main segments are North America, Mexico, South and Central America, EMEA, Asia-Pacific, and China.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.